Comparative Pharmacology
Head-to-head clinical analysis: KETOZOLE versus MYHIBBIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: KETOZOLE versus MYHIBBIN.
KETOZOLE vs MYHIBBIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ketoconazole is an imidazole antifungal agent that inhibits fungal cytochrome P450 14α-demethylase, thereby blocking the conversion of lanosterol to ergosterol, a key component of the fungal cell membrane. This leads to increased membrane permeability and cell death.
Myhibbin is a selective inhibitor of inosine monophosphate dehydrogenase (IMPDH), thereby blocking the de novo synthesis of guanosine nucleotides. This inhibits T- and B-lymphocyte proliferation and antibody production.
200 mg orally once daily with food.
MYHIBBIN is not a recognized FDA-approved drug. No standard dosing information is available.
None Documented
None Documented
Terminal elimination half-life is approximately 2 hours (range 1.5–3.5 hours). Clinically, duration of antifungal effect extends beyond plasma half-life due to persistent tissue levels.
Terminal half-life: 12-15 hours in adults; prolonged in renal impairment (up to 30 hours)
Primarily hepatic metabolism; renal excretion of unchanged drug <1%. Biliary/fecal excretion accounts for ~20-35% of metabolites.
Renal excretion as unchanged drug (70-80%), biliary/fecal (15-20%)
Category C
Category C
Antifungal
Antifungal